ReviewCytotherapy2015
Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells.
Review in Cytotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Who cites it
71 citing papers in PubMed.
- Review
- Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton's Jelly Mesenchymal Stem Cells in the Orchestrum.Brain sciences · 2026Review
- Low oxygen preconditioning of umbilical cord MSCs: from biological to mechanistic innovation.Journal of translational medicine · 2026Review
- eSolubilized amniotic membrane ECM as a promising biological surface treatment approach for 3D-printed bone tissue engineering scaffolds.Scientific reports · 2025Article
- Quercetin-loaded mesenchymal stem cell derived extracellular vesicles enhance ovarian function in a cyclophosphamide induced ovarian damage.Journal of ovarian research · 2025Article
- Enhancing the Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells for Osteoarthritis: The Role of Platelet-Rich Plasma and Extracellular Vesicles.International journal of molecular sciences · 2025Article
- Comparing the growth kinetics and characteristics of Wharton's jelly derived mesenchymal stem cells expanded using different culture mediums.Cytotechnology · 2025Article
- Isolation of Wharton's Jelly-Derived Mesenchymal Stromal/Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Impact of delayed cord clamping on mesenchymal, hemopoietic progenitor, and immune cells in very preterm neonates.Frontiers in pediatrics · 2025Article
- The order of green and red LEDs irradiation affects the neural differentiation of human umbilical cord matrix-derived mesenchymal cells.Scientific reports · 2024Article
- Therapeutic efficacy of thrombin-preconditioned mesenchymal stromal cell-derived extracellular vesicles on Escherichia coli-induced acute lung injury in mice.Respiratory research · 2024Article
- Article
- Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects.World journal of stem cells · 2024Review
- Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.Frontiers in medicine · 2024Review
- Liquefied capsules containing nanogrooved microdiscs and umbilical cord-derived cells for bone tissue engineering.Open research Europe · 2024Article
- Immune regulation is more effective in the U937 inflammation model with mesenchymal stem cell extracellular vesicles stimulated by pro-inflammatory cytokines.Central-European journal of immunology · 2024Article
- Advancements in Umbilical Cord Biobanking: A Comprehensive Review of Current Trends and Future Prospects.Stem cells and cloning : advances and applications · 2024Review
- Umbilical cord-derived mesenchymal stem cells cultured in the MCL medium for aplastic anemia therapy.Stem cell research & therapy · 2023Article
- Review
- Cord management in non-vigorous newborns.Seminars in perinatology · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mesenchymal stromal cells (MSCs) are multi-potent cells that have the capability of differentiating into adipogenic, osteogenic, chondrogenic and neural cells. With these multiple capabilities, MSCs have been highly regarded as an effective transplantable cell source for regenerative medicine. A large bank of these cells can be found in several regions of the human umbilical cord, including the umbilical cord lining, the subendothelial layer, the perivascular zone and, most important, in Wharton jelly (WJ). These cells, all umbilical cord-derived MSCs, are durable, have large loading capacities and are considered ethical to harvest because the umbilical cord is often considered waste. These logistical advantages make WJ as appealing source of stem cells for transplant therapy. In particular, WJ is a predominantly good source of cells because MSCs in WJ are maintained in an early embryologic phase and therefore have retained some of the primitive stemness properties. WJ-MSCs can easily differentiate into a plethora of cell types leading to a variety of applications. In addition, WJ-MSCs are slightly easier to harvest compared with other MSCs (such as bone marrow-derived MSCs). The fascinating stemness properties and therapeutic potential of WJ-MSCs provide great promise in many aspects of regenerative medicine and should be considered for further investigations as safe and effective donor cells for transplantation therapy in many debilitating disorders, which are discussed here. We previously reviewed the therapeutic potential of WJ-MSCs and now provide an update on their recent preclinical and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.